Original Contribution

Reproductive and Hormonal Factors in Association With Ovarian Cancer in the Netherlands Cohort Study

M. G. M. Braem, N. C. Onland-Moret, P. A. van den Brandt, R. A. Goldbohm, P. H. M. Peeters, R. F. P. M. Kruitwagen, and L. J. Schouten*

* Correspondence to Dr. L. J. Schouten, Department of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands (e-mail: lj.schouten@epid.unimaas.nl).

Initially submitted April 8, 2010; accepted for publication July 14, 2010.

Parity, oral contraceptive use, and hysterectomy are known to protect against ovarian cancer, whereas the effect of other reproductive factors remains unclear. The authors investigated the association between several reproductive and hormonal factors and the risk of epithelial invasive ovarian cancer among postmenopausal women participating in the Netherlands Cohort Study on Diet and Cancer. Information on reproductive history and exogenous hormone use was obtained through a self-administered questionnaire at baseline in 1986. After 16.3 years of follow-up, 375 cases and 2,331 subcohort members were available for case-cohort analysis. Ovarian cancer risk was reduced for parous women, with increasing parity, and for hysterectomized women. Moreover, the authors found evidence that oral contraceptive use is protective against ovarian cancer, even when initiated at an older age. In addition, a reduced risk was observed for each year reduction in age at natural menopause and per year reduction in total menstrual life span. A small increased risk was observed with prolonged time to pregnancy, but no difference was found between ever-married nulliparous women and never-married nulliparous women. Moreover, no associations were observed for age at first birth, age at menarche, age at first and last use of oral contraceptives, and use of hormone replacement therapy.

hormones; infertility; ovarian neoplasms; prospective studies; reproductive history

Abbreviations: CI, confidence interval; HR, hazard ratio; HRT, hormone replacement therapy; OC, oral contraceptive.

Ovarian cancer is the fifth most common cancer among women in Europe (1). Unknown pathogenesis and late diagnosis contribute to poor survival. Different reproductive and hormonal factors have been studied to clarify their influence on ovarian carcinogenesis. Epidemiologic studies consistently show a protective effect of parity, oral contraceptive (OC) use, and hysterectomy (2–22). Less clear are the effects of age at first birth and timing of OC use. Moreover, results for other reproductive risk factors, such as age at menarche, age at menopause, and hormone replacement therapy (HRT), remain conflicting.

The increased risk for nulliparous women could, in part, reflect an association between ovarian cancer and subfertility. Generally, no strong overall associations have been found between subfertility and ovarian cancer (23–29). However, an increased risk has been observed in some studies for subfertile women who remained childless (20, 21, 23, 25, 26, 28).

Most studies that examined reproductive and hormonal factors used a case-control design, which may suffer from recall and selection bias. Moreover, interpretation of results has been hampered by inadequate control for potential confounding factors, small sample sizes, and differences in reference groups used. We conducted a large prospective study among postmenopausal women within the Netherlands Cohort Study on Diet and Cancer to examine the association of fertility and of reproductive and hormonal factors with the risk of epithelial ovarian cancer.

MATERIALS AND METHODS

The cohort

The prospective Netherlands Cohort Study on Diet and Cancer started in September 1986 with the enrollment of
participants aged 55–69 years (30). In total, 62,573 women were included, who were all presumed to be postmenopausal. For efficiency reasons, data processing and analysis were based on the case-cohort approach. Cases were derived from the entire cohort, and number of person-years at risk for the entire cohort was estimated from a subcohort of 2,589 women randomly sampled from the total cohort at baseline. The subcohort has been contacted by letter every 2 years regarding migration and vital status. In case of no response, the municipal population registries were contacted. No women were lost to follow-up. For more details on the Netherlands Cohort Study on Diet and Cancer, refer to the article by van den Brandt et al. (30). After exclusion of women with prevalent malignancy at baseline (other than nonmelanoma skin cancer) and women who, at baseline, reported they had undergone an oophorectomy, 2,406 female subcohort members remained available.

The study protocol of the Netherlands Cohort Study on Diet and Cancer was approved by the medical ethics committees of the University Hospital Maastricht in February 1985 and TNO Nutrition and Food Research in July 1986.

**Identification of cases**

Incident cancer cases were identified by computerized record linkage of the entire cohort to the Netherlands Cancer Registry and the Netherlands Pathology Registry (30, 31). The completeness of cancer follow-up was estimated to be more than 95% (32). During a follow-up period of 16.3 years, 394 microscopically confirmed cases of invasive epithelial ovarian cancer were identified. Women with incomplete covariate data (i.e., parity (parous/nulliparous, number of children) and OC use (never/ever)) were excluded, leaving 375 cases and 2,331 subcohort members for analysis.

**Questionnaire data**

The baseline questionnaire included self-reported information on year of first marriage, number of children, year of first birth, age at menarche, age at menopause, and how menopause was induced. Participants were asked whether they had ever used OCs (yes/no), at which age they started and stopped using OCs, and the total duration of use (in years). In addition, they were asked whether they had ever used HRT and in which year they started and stopped using it. In an open question, participants were asked which types of surgery they had undergone. This item enabled us to define whether women had undergone oophorectomy or hysterectomy, or a combination of both. For women reporting a hysterectomy, age at menopause could be misclassified because many of these women reported that their menopause started on the date of the surgery. Therefore, we restricted our analysis of age at menopause to women experiencing a natural menopause.

Reductions in years of menstrual life span were estimated using different indicators, according to the studies of Dossus et al. (33) and Pelucchi et al. (34). We estimated the influence on ovarian cancer for each year that menarche is delayed; for each year menopause is advanced in time (entering age at natural menopause into the model with a minus sign); per year of being pregnant (calculated as number of children × 0.75); per year of OC use; per year reduction in time between menarche and menopause; and per year reduction in total menstrual life span. The latter was estimated by calculating the time between age at menarche and age at natural menopause and subsequently subtracting years of pregnancy and years of OC use. Time to pregnancy was defined as the time between marriage and first birth. To analyze time to pregnancy, we excluded women who used OCs prior to the birth of their first child (n = 5).

**Data analysis**

Person-years at risk were calculated from the start of the study until ovarian cancer diagnosis, death, emigration, or end of follow-up (December 31, 2002). The association between various reproductive and hormonal factors and risk of ovarian cancer was evaluated in age-adjusted and multivariate case-cohort analyses using Cox proportional hazards models. Standard errors were estimated using the robust Huber-White sandwich estimator to account for additional variance introduced by sampling from the cohort. This method is equivalent to the variance-covariance estimator presented by Barlow (35).

Analyses were adjusted a priori for age, parity (number of children), and OC use (ever/never) because of their established influence on ovarian cancer development. We considered other potential confounders based on evidence from epidemiologic literature, including height (cm), body mass index (kg/m²), family history of ovarian or breast cancer (yes/no), educational level (primary school, lower vocational school, high school/intermediate vocational school, higher vocational school/university), nonoccupational physical activity (≤30 minutes/day, 31–60 minutes/day, 61–90 minutes/day, >90 minutes/day), smoking status (never, current, former), and all other reproductive and hormonal factors under study. Confounding was evaluated starting with a full multivariate model and using a backward elimination approach (36). If eliminating a covariate from the full Cox regression model changed the hazard ratio by 10% or more, the covariate was considered a confounder and was retained in the model. Otherwise, that covariate was dropped from the multivariate model. None of the potential confounders met this criterion. Therefore, all models were adjusted for only age, parity, and OC use. Moreover, ages at first and last use of OC and HRT were additionally adjusted for duration of use of OC and HRT, respectively.

We also examined whether results differed by age, parity, OC use, hysterectomy, family history of ovarian or breast cancer, body mass index, and smoking status. We used both stratified analyses and the likelihood ratio test to compare proportional hazards regression models with and without the interaction term (37). The proportional hazards assumption was tested using the scaled Schoenfeld residuals and with graphic tests (38). To calculate the P value for the trend test, we assigned participants the median value of each category and treated this variable as a continuous term in the model (36). Two-sided P values are reported throughout the paper and were considered statistically significant if <0.05. All
analyses were performed with the Stata statistical software package (release 9.1; Stata Corporation, College Station, Texas).

RESULTS

Baseline characteristics of cases and subcohort members are presented in Table 1. Compared with subcohort members, ovarian cancer cases were slightly taller and heavier, and they were more likely to be never smokers. Of the ovarian cancers, 182 were serous invasive (48.5%), 31 were endometrioid (8.3%), 35 were mucinous (9.3%), and 15 were clear-cell (4.0%). The mean age at diagnosis was 70.4 (standard deviation, 5.9) years.

Table 2 shows the associations between various reproductive factors and ovarian cancer risk. Compared with nulliparous women, parous women had a lower risk (hazard ratio (HR) = 0.71, 95% confidence interval (CI): 0.55, 0.93). Moreover, risk decreased by almost 10% for each additional livebirth, which showed a statistically significant trend (P < 0.001). In addition, ovarian cancer risk was decreased for women with a history of hysterectomy (HR = 0.50, 95% CI: 0.34, 0.72). Age at first birth was not associated with ovarian cancer risk. Observations were essentially unchanged after further adjustment for number of full-term pregnancies.

Women who ever used OCs had an almost 30% reduced ovarian cancer risk compared with those who never used OCs (HR = 0.71, 95% CI: 0.52, 0.97; Table 3). This finding was most pronounced for women who used OCs for more than 5 years (HR = 0.47, 95% CI: 0.30, 0.76). We observed no statistically significant associations for age at first and last use of OC, ever use of HRT, and age at first and last use of HRT. For duration of HRT use, the proportional hazards assumption did not hold, and the number of cases in the predefined intervals subsequently became too small to validly interpret the results. The observed risk estimates remained essentially the same after adjustment for age at menopause and induced menopause.

We examined the association between ovarian cancer and different exposures known to reduce menstrual life span, mutually adjusted for each other (Table 4). For all of the exposures, except for delay in age at menarche, trends of decreasing risk with decreasing years of menstrual life span were found. We observed a lower ovarian cancer risk of 2% and 5% per year reduction in age at natural menopause and per year of OC use, respectively, and a 10% risk reduction per year of being pregnant. Furthermore, we observed a reduced risk for each year reduction in time between menarche and menopause (HR = 0.98, 95% CI: 0.95, 1.00). Moreover, we observed a reduced risk for each year reduction in total menstrual life span (HR = 0.97, 95% CI: 0.95, 0.99). This association did not change after exclusion of women whose menopause was induced.

Table 1. Baseline Characteristics of Cases and Subcohort Members of the Netherlands Cohort Study on Diet and Cancer, 1986–2002

|                  | Cases (n = 375) | Subcohort (n = 2,331) |
|------------------|----------------|-----------------------|
| Age, years       | 62.0 (4.3)     | 61.5 (4.3)            |
| Height, cm       | 165.8 (6.1)    | 165.2 (6.2)           |
| Weight, kg       | 69.7 (10.8)    | 68.5 (10.2)           |
| Body mass index, kg/m² | 25.2 (3.5)     | 25.1 (3.5)            |
| Family history of ovarian or breast cancer | 30 8.0 | 199 8.5 |
| Educational level |                |                       |
| Primary school   | 129 34.9       | 806 35.0              |
| Lower vocational school | 96 26.0 | 539 23.4 |
| High school/intermediate vocational school | 118 31.9 | 764 33.2 |
| Higher vocational school/university | 27 7.3 | 191 8.3 |
| Smoking status   |                |                       |
| Never            | 241 64.3       | 1,361 58.4            |
| Current          | 67 17.9        | 491 21.1              |
| Former           | 67 17.9        | 479 20.6              |

Abbreviation: SD, standard deviation.
of cases became very small for this subanalysis, the confidence intervals became relatively wide.

**DISCUSSION**

In this prospective study, parity, OC use, and hysterectomy substantially reduced epithelial ovarian cancer risk. In addition, ovarian cancer risk was reduced with earlier age at menopause, per year of being pregnant, for shorter time intervals between menarche and menopause, and per year reduction in total menstrual life span. For pregnancies, the protective effect was strongest. Furthermore, we observed an increased ovarian cancer risk by increasing time to pregnancy.

We need to underscore some population characteristics that make this cohort unique but must be kept in mind when interpreting the results. In our cohort, birth rates were high, with a median of 3 and a range of 0–15. Only 24.1% of these women reported ever use of OCs. In addition, women started using OCs at a relatively late age: a mean of 40 years. All women were postmenopausal, and the mean age of participants at baseline was 62 years. Therefore, results may not be generalizable to premenopausal women.

The major strengths of our study include its prospective design, with detailed exposure and covariate assessment prior to diagnosis. Subjects were followed for up to 16.3 years, with a nearly complete follow-up.

A potential source of bias is possible underreporting of oophorectomies by hysterectomized women. Because excluding hysterectomized women did not alter the results, this factor is unlikely to have substantially affected our results. In addition, recall of reproductive factors and surgeries by women aged 55–69 years could lead to some misclassification. Pregnancies are expected to be recalled accurately regardless of age; however, other reproductive and hormonal factors are likely to be recalled less accurately. Exposure and covariate information was assessed independently of the outcome; therefore, misclassification is most likely undifferential. Another limitation of our study is that a proxy had to be used for reduced fertility. Although time to pregnancy is a validated measure of biologic fertility, we were not able to directly determine it (39–41). Therefore, we used time to childbirth after marriage as a surrogate measure for time to pregnancy. Because birth control measures were sparse during these women’s reproductive life, especially in the years between their marriage and their first

**Table 2. Reproductive Factors in Association With Ovarian Cancer Risk in the Netherlands Cohort Study on Diet and Cancer, 1986–2002**

| Parity           | No. of Cases | Person-Years in the Subcohort | Age Adjusted | Multivariate Adjusted* |
|------------------|--------------|-------------------------------|--------------|------------------------|
|                  |              |                               | HR  | 95% CI      | HR  | 95% CI      |
| Nulliparous      | 88           | 5,961.0                       | 1.00 | Referent    | 1.00 | Referent    |
| Parous           | 287          | 28,624.5                      | 0.68 | 0.53, 0.89  | 0.71 | 0.55, 0.93  |
| No. of children  |              |                               |              |            |              |            |
| 0                | 88           | 5,961.0                       | 1.00 | Referent    | 1.00 | Referent    |
| 1–2              | 130          | 10,539.9                      | 0.85 | 0.63, 1.15  | 0.88 | 0.65, 1.19  |
| 3–4              | 108          | 11,653.7                      | 0.64 | 0.47, 0.86  | 0.66 | 0.49, 0.90  |
| >4               | 49           | 6,430.9                       | 0.51 | 0.35, 0.74  | 0.53 | 0.36, 0.78  |
| P for trendb     |              |                               | <0.001       |             | <0.001       |             |
| Overall trend per term pregnancy | 375          | 34,585.5                      | 0.90 | 0.85, 0.95  | 0.91 | 0.86, 0.96  |
| Age at first birth, years |            |                               |              |            |              |            |
| <20              | 3            | 690.4                         | 0.51 | 0.16, 1.61  | 0.51 | 0.15, 1.69  |
| 20–24            | 63           | 7,331.3                       | 1.00 | Referent    | 1.00 | Referent    |
| 25–29            | 152          | 14,043.6                      | 1.24 | 0.93, 1.67  | 1.25 | 0.91, 1.71  |
| ≥30              | 68           | 6,381.7                       | 1.20 | 0.85, 1.69  | 1.21 | 0.83, 1.75  |
| P for trendb     |              |                               | 0.16          |             | 0.15        |             |
| Overall trend per year increase | 286          | 28,447.0                      | 1.02 | 0.99, 1.05  | 1.02 | 0.99, 1.05  |
| Hysterectomy     |              |                               |              |            |              |            |
| No               | 342          | 28,825.2                      | 1.00 | Referent    | 1.00 | Referent    |
| Yes              | 33           | 5,760.2                       | 0.49 | 0.34, 0.72  | 0.50c | 0.34, 0.72  |

Abbreviations: CI, confidence interval; HR, hazard ratio.

a Adjusted for age and oral contraceptive use (ever/never).

b Calculated by using the median for each category and modeled as a continuous variable.

c Additionally adjusted for parity (number of children).
child, this measure should adequately estimate time to pregnancy. For the same reason, nulliparity among married women might be seen as a valuable proxy for reduced fertility. Nevertheless, results should be interpreted with caution. Finally, the sample size limited our ability to analyze data by histologic subtype.

In line with our results, other studies consistently observed a decreased ovarian cancer risk for parous women, with increasing parity (2, 3, 5, 6, 11, 15, 16, 18, 19, 21, 22), for OC users, and with increasing duration of OC use (7, 12–15, 21, 22, 42–44). OCs were introduced in the early 1960s, when women in our study population were aged 33–47 years. Mean age at first OC use was 40 years. Our results thus imply that OC use is preventive against ovarian cancer, even when initiated at an older age. The incessant ovulation hypothesis, proposed by Fathalla (45), postulates that ovarian cancer develops through repeated trauma to the covering epithelium of the ovary during ovulation.

Recent findings implicate the fallopian tube fimbria as a possible site of origin of ovarian carcinomas (46–48). Piek et al. (49) revisited the incessant ovulation hypothesis and suggested that incessant ovulation increases ovarian cancer risk by increasing the risk of inclusion of exfoliated tubal epithelial cells into the ovarian stroma and by increasing mitotic activity within tubal epithelium. According to this hypothesis, parity and OC use reduce ovarian cancer risk by reducing the lifetime ovulation numbers. Also concordant with this hypothesis, we observed a clear trend per year reduction in total menstrual life span. Although we could estimate menstrual life span only crudely, our observation of a 3% decrease in risk for each year reduction in total menstrual life span is consistent with the 2.5%–6% increase in ovarian cancer risk associated with each ovulation year observed in other studies (19, 34, 50).

When all factors relating to menstrual life span were analyzed simultaneously, we found that pregnancies had

| Table 3. Exogenous Hormone Use in Association With Ovarian Cancer Risk in the Netherlands Cohort Study on Diet and Cancer, 1986–2002 |
|---------------------------------------------------------------|
| No. of Cases | Person-Years in the Subcohort | Age Adjusted | Multivariate Adjusted* |
|---------------|------------------------------|--------------|-----------------------|
|               |                              | HR | 95% CI | HR | 95% CI |
| OC use        |                              |    |        |    |        |
| Never         | 310                          | 25,916.9 | 1.00  | Referent | 1.00  | Referent |
| Ever          | 65                           | 8,668.6  | 0.67  | 0.49, 0.91 | 0.71  | 0.52, 0.97 |
| Duration of OC use, years | Never | 310 | 25,916.9 | 1.00 | Referent | 1.00 | Referent |
|                | ≤5                           | 32  | 3,246.6 | 0.87 | 0.58, 1.31 | 0.92 | 0.61, 1.38 |
|                | >5                           | 22  | 4,443.2 | 0.44 | 0.28, 0.71 | 0.47 | 0.30, 0.76 |
| Age at first OC use, years | ≤40 | 31  | 5,211.8 | 1.00 | Referent | 1.00 | Referent |
|               | >40                          | 32  | 3,170.7 | 1.36 | 0.78, 2.39 | 1.28 | 0.68, 2.43 |
| Age at last OC use, years | ≤45 | 18  | 2,910.8 | 0.91 | 0.51, 1.60 | 0.51 | 0.24, 1.10 |
|               | >45                          | 42  | 5,282.9 | 1.00 | Referent | 1.00 | Referent |
| HRT use       | Never                        | 314 | 28,679.8 | 1.00 | Referent | 1.00 | Referent |
| Ever          | 44                           | 4,175.4 | 0.97  | 0.69, 1.36 | 0.97 | 0.69, 1.37 |
| Age at first HRT use, years | ≤50 | 22  | 2,114.4 | 1.00 | Referent | 1.00 | Referent |
|               | >50                          | 17  | 1,500.2 | 1.10 | 0.56, 2.18 | 0.96 | 0.47, 1.97 |
| Age at last HRT use, years | ≤50 | 12  | 1,275.0 | 1.00 | Referent | 1.00 | Referent |
|               | >50                          | 28  | 2,241.0 | 1.28 | 0.61, 2.66 | 1.39 | 0.63, 3.03 |

Abbreviations: CI, confidence interval; HR, hazard ratio; HRT, hormone replacement therapy; OC, oral contraceptive.

* Adjusted for age and parity (number of children).

b Additionally adjusted for duration of OC use.

c Additionally adjusted for duration of HRT use.
and entered into the model with a minus sign. Menarche
contraceptive.
Table 5. Reduced Fertility in Association With Ovarian Cancer Risk

| Risk for each year that menarche is delayed | 313 | 26,501.9 | 1.02a | 0.95, 1.09 |
| Risk for each year that menopause is advanced in timeb | 313 | 26,501.9 | 0.98b | 0.95, 1.01 |
| Risk per year of OC use | 313 | 26,501.9 | 0.95a | 0.91, 0.99 |
| Risk per year of being pregnantc | 313 | 26,501.9 | 0.90c | 0.83, 0.98 |
| Risk per year reduction in time between menarche and menopaused | 349 | 31,796.0 | 0.98d | 0.95, 1.00 |
| Risk per year reduction in total menstrual life spane | 313 | 26,501.9 | 0.97e | 0.95, 0.99 |

Abbreviations: CI, confidence interval; HR, hazard ratio; OC, oral contraceptive.

a Mutually adjusted for the other risk factors in the table (except for year reduction in time between menarche and menopause and year reduction in total menstrual life span) and for age.
b Age at natural menopause was entered in the model with a minus sign.
c Calculated as follows: (number of children × 0.75).
d Calculated as the time interval between menarche and menopause and entered into the model with a minus sign.
e Age adjusted.

Breastfeeding, menstrual patterns, and incomplete pregnancies. Besides, accurate estimation of menstrual life span is limited by the lack of information on breastfeeding, menstrual patterns, and incomplete pregnancies. Therefore, our association for total menstrual life span might be underestimated. The World Cancer Research Fund concluded in 2007, based on 1 cohort and 10 case-control studies, that there is only limited evidence suggesting that lactation protects against ovarian cancer (51). However, 1 cohort and 1 case-control study, published after the World Cancer Research Fund report, found inverse associations between total duration of breastfeeding and ovarian cancer (52, 53). Therefore, our observation of a stronger protective effect of pregnancies compared with other factors could reflect a protective role of breastfeeding.

Excessive stimulation of ovarian tissue by hormones such as pituitary gonadotropins, estrogens, and androgens is also suggested to increase ovarian cancer risk (54, 55). Pregnancies and OCs suppress pituitary gonadotropin secretion. Moreover, OCs reduce endogenous androgen and estrogen levels. Another mechanism by which parity and OCs might reduce ovarian cancer risk is by increasing circulating progesterone levels. Moreover, it has been proposed that pregnancies clear malignantly transformed cells from the ovaries (2). This alternate hypothesis was recently extended to the cell clearance hypothesis supported by Rostgaard et al. (56), which is based on the idea that a fraction of the genetically modified (premalignant) cells are cleared after each pregnancy.

In line with other studies (4, 8–10, 13, 17, 21), we found that risk of ovarian cancer was decreased for women with a history of hysterectomy. According to the androgen hypothesis, hysterectomy might reduce ovarian cancer by reducing testosterone levels (57). It also eliminates or reduces uterine growth factors involved in ovarian cancer pathogenesis (8). Moreover, hysterectomy alters ovarian blood flow and consequently impairs ovarian function (58–60). Furthermore, hysterectomy may reduce ovarian cancer development by blocking access of ovarian carcinogens that enter the peritoneal cavity via the vagina (4). Recently, a novel hypothesis regarding the origin of ovarian cancer was proposed by Massuger et al. (61), in which serous ovarian cancer is hypothesized to originate in the uterus. This hypothesis, if correct, easily explains the protective effect of hysterectomies.

In contrast with other studies (2, 18, 21, 22, 62), we did not observe a reduced ovarian cancer risk with increasing age at first birth. A higher age at first birth in other studies could indicate a longer duration of OC use; in our population, as stated before, women started using OCs at an older age.

We observed a decreased ovarian cancer risk per year that menopause was advanced in time, which is consistent with most studies (9, 34, 63–66) but contrasts with others (18, 21, 67). A younger age at menopause indicates less exposure to ovulatory cycles and might therefore decrease ovarian cancer risk according to the incessant ovulation hypothesis.

Our finding of a lack of association between age at menarche and ovarian cancer risk is in line with most studies (18, 34, 63, 67, 68), but not all (15, 21). We also did not observe a clear association of age at first and last use of OCs with ovarian cancer risk, which again is consistent with most studies (12, 14, 42, 44), but not all (43, 69).

In this study, ever use of HRT was not associated with ovarian cancer risk. This result agrees with results of

Table 5. Reduced Fertility in Association With Ovarian Cancer Risk

| Cases | Person-Years in the Subcohort | HRa | 95% CI |
|-------|------------------------------|-----|--------|
| Time to pregnancyb | 282 | 28,017.8 | 1.04 | 0.99, 1.09 |
| Nulliparity among ever-married womenc | 39 | 5,961.0 | 1.04 | 0.65, 1.68 |

Abbreviations: CI, confidence interval; HR, hazard ratio.

a Adjusted for age.
b Calculated as time between marriage and first birth (in years).
c Ever-married women versus never-married women.
a collaborative analysis of 12 case-control studies by Whittemore et al. (21), but it contradicts results from most studies, including 4 meta-analyses, that found an increased ovarian cancer risk for ever users of HRT (15, 21, 70–74). Consistent with the estrogen hypothesis, associations in these studies were mostly stronger for unopposed estrogen therapy users (54, 55). Because progestins were added to HRT in 1985 (75), we assume that almost all HRT prescribed before the start of the Netherlands Cohort Study on Diet and Cancer consisted of oral estrogen therapy. Most likely, the group of women who used HRT in our population was too small to detect associations.

If increased ovarian cancer risk for nulliparous women stems from difficulties in conceiving, ovarian cancer risk should be higher with prolonged time to pregnancy and for nulliparous women who married compared with nulliparous women who never married. Indeed, prolonged time to pregnancy elevated ovarian cancer risk in our study, which is consistent with previous studies (20, 21, 25, 26, 28). However, we did not observe a difference between ever-married nulliparous women and never-married nulliparous women. This lack of association could be due to the relatively small number of cases for this particular analysis. Therefore, we cannot form any reliable conclusion regarding the effect of subfertility on ovarian cancer risk.

The analysis according to histologic subtype was limited by the small number of cases in the different strata and the relatively high number of cases with not-otherwise-specified adenocarcinoma (International Classification of Diseases for Oncology code 8140/3). Therefore, we were unable to observe clear differences between these subtypes.

In conclusion, we observed a reduced ovarian cancer risk with increasing parity, increasing duration of OC use, hysterectomy, younger age at natural menopause, and by per year reduction of total menstrual life span. We provided evidence that OC use is protective, even when initiated at an older age. Moreover, we found an increased ovarian cancer risk with prolonged time to pregnancy. Additional research is needed to further elucidate the different biologic pathways of ovarian carcinogenesis.

ACKNOWLEDGMENTS

Author affiliations: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands (M. G. M. Braem, N. C. Onland-Moret, P. H. M. Peeters); Department of Epidemiology, GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands (P. A. van den Brandt, L. J. Schouten); Department of Prevention and Health, TNO Quality of Life, Leiden, the Netherlands (R. A. Goldbohm); and Department of Obstetrics and Gynaecology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands (R. F. P. M. Kruitwagen).

This study was financially supported by the Dutch Cancer Society (UU2008-4267).

The authors thank the cancer registries (Comprehensive Cancer Centre Amsterdam (IKA), Maastricht Cancer Registry Comprehensive Cancer Centre Limburg (IKL), Utrecht Cancer Registry Comprehensive Cancer Centre Midden-Nederland (IKMN), North Netherlands Cancer Registry Comprehensive Cancer Centre North Netherlands (IKN), East Netherlands Cancer Registry Comprehensive Cancer Centre East (IKO), Rotterdam Cancer Registry Comprehensive Cancer Centre Rotterdam (IKR), Comprehensive Cancer Centre Stedendriehoek Twente (IKST), Comprehensive Cancer Centre West (IKW), Eindhoven Cancer Registry, Comprehensive Cancer Centre South (IKZ), and Vereniging van Integrale Kankercentra (VIKC)), as well as the Netherlands nationwide registry of pathology (PALGA).

They also thank Dr. A. Volovics and Dr. A. Kester for statistical advice; S. van de Crommert, H. Brands, J. Nelissen, C. de Zwart, M. Moll, W. van Dijk, M. Jansen, and A. Pisters for assistance; and H. van Montfort, T. van Moergastel, L. van den Bosch, J. Berben, and R. Schmeitz for programming assistance.

Conflict of interest: none declared.

REFERENCES

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–592.
2. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344(8932):1250–1254.
3. Albrektsen G, Heuch I, Kvale G. Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes Control. 1996;7(4):421–427.
4. Chiaffarino F, Parazzini F, Decarli A, et al. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol. 2005;97(2):318–322.
5. Chiaffarino F, Parazzini F, Negri E, et al. Time since last birth and the risk of ovarian cancer. Gynecol Oncol. 2001;81(2):233–236.
6. Chiaffarino F, Pelucchi C, Parazzini F, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol. 2001;12(3):337–341.
7. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–314.
8. Cramer DW, Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol. 1995;5(4):310–314.
9. Gates MA, Rosner BA, Hecht JL, et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171(1):45–53.
10. Green A, Purdie D, Bain C, et al. Tubal sterilisation, hysterec- tomy and decreased risk of ovarian cancer. Survey of Women’s Health Study Group. Int J Cancer. 1997;71(6):948–951.
11. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76(2):284–290.
12. Lurie G, Wilkens LR, Thompson PJ, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008;19(2):237–243.

13. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol. 2001;11(8):568–574.

14. Moorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol. 2008;167(9):1059–1069.

15. Moorman PG, Palmieri RT, Akushevich L, et al. Ovarian cancer risk factors in African-American and white women. Am J Epidemiol. 2009;170(5):598–606.

16. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140(7):585–597.

17. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 1996;5(11):933–935.

18. Tittus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84(5):714–721.

19. Tung KH, Wilkins LR, Wu AH, et al. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: re-visiting the incessant ovulation hypothesis. Am J Epidemiol. 2005;161(4):321–329.

20. Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007;166(8):894–901.

21. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136(10):1184–1203.

22. Zhang M, Lee AH, Binns CW. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol. 2004;92(1):320–326.

23. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004;82(2):405–414.

24. Hardiman P, Nieto JJ, MacLean AB. Infertility and ovarian cancer. Gynecol Oncol. 2000;76(1):1–2.

25. Mosgaard BJ, Lidgaard O, Kjaer SK, et al. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril. 1997;67(6):1005–1012.

26. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155(3):217–224.

27. Rodriguez C, Tatham LM, Calle EE, et al. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control. 1998;9(6):645–651.

28. Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004;160(11):1070–1078.

29. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multi-ethnic case-control study. Am J Epidemiol. 2003;158(7):629–638.

30. van den Brandt PA, Goldbohm RA, van’t Veer P, et al. A large-scale prospective cohort study on diet and cancer in the Netherlands. J Clin Epidemiol. 1990;43(3):285–295.

31. van den Brandt PA, Schouten LJ, Goldbohm RA, et al. Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research. Int J Epidemiol. 1990;19(3):553–558.

32. Goldbohm RA, van den Brandt PA, Dorant E. Estimation of the coverage of Dutch municipalities by cancer registries and PALGA based on hospital discharge data. Tijdschr Soc Gezondheidsz. 1994;72:80–84.

33. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;127(2):442–451.

34. Pelucchi C, Galeone C, Talamini R, et al. Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol. 2007;196(1):83.e1–87.e1. (doi:10.1016/j.ajog.2006.06.088).

35. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50(4):1064–1072.

36. Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott-Raven; 2008.

37. Kleinbaum DG. Survival Analysis. New York, NY: Springer; 1996.

38. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239–241.

39. Greenhall E, Vessey M. The prevalence of subfertility: a review of the current confusion and a report of two new studies. Fertil Steril. 1990;54(6):978–983.

40. Joffe M. Time to pregnancy: a measure of reproductive function in either sex. Asclepios Project. Occup Environ Med. 1997;54(5):289–295.

41. Joffe M, Paranjothy S, Fielder H, et al. Use of time to pregnancy in environmental epidemiology and surveillance. J Public Health (Oxf). 2008;30(2):178–185.

42. Bosetti C, Negri E, Trichopoulous D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer. 2002;102(3):262–265.

43. Kumle M, Weiderpass E, Braaten T, et al. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Br J Cancer. 2004;90(7):1386–1391.

44. Ness RB, Grasso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progesterin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol. 2000;152(3):233–241.

45. Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia [letter]? Lancet. 1971;2(7716):163.

46. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010;2010:932371. (doi:10.1155/2010/932371).

47. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer and its clinical impact. Clin Oncol. 2000;1386–1391.

48. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284–5293.

49. Piek JM, Kenemans P, Zweemer RP, et al. Ovarian carcino genesis, an alternative theory [letter]? Lancet. 1971;2(7716):163.

50. Piepkorn K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284–5293.

51. Purdie DM, Bain CJ, Siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003;104(2):228–232.

52. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the
52. Jordan SJ, Siskind V, Green AC, et al. Breastfeeding and risk of epithelial ovarian cancer. *Cancer Causes Control*. 2010; 21(1):109–116.

53. Danforth KN, Tworoger SS, Hecht JL, et al. Breastfeeding and risk of ovarian cancer in two prospective cohorts. *Cancer Causes Control*. 2007;18(5):517–523.

54. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. *J Natl Cancer Inst*. 1998;90(23):1774–1786.

55. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. *Cancer Epidemiol Biomarkers Prev*. 2005;14(1):98–107.

56. Rostgaard K, Wohlfahrt J, Andersen PK, et al. Does pregnancy induce the shedding of premalignant ovarian cells? *Epidemiology*. 2003;14(2):168–173.

57. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. *Oncology*. 1999;57(suppl 2):45–48.

58. Chan CC, Ng EH, Ho PC. Ovarian changes after abdominal hysterectomy for benign conditions. *J Soc Gynecol Investig*. 2005;12(1):54–57.

59. Halmesmäki KH, Hurskainen RA, Cacciatore B, et al. Effect of hysterectomy or LNG-IUS on serum inhibin B levels and ovarian blood flow. *Maturitas*. 2007;57(3):279–285.

60. Xiangying H, Lili H, Yifu S. The effect of hysterectomy on ovarian blood supply and endocrine function. *Climacteric*. 2006;9(4):283–289.

61. Massuger L, Roelofs T, Ham M, et al. The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. *Med Hypotheses*. 2010;74(5):859–861.

62. Whiteman DC, Siskind V, Purdie DM, et al. Timing of pregnancy and the risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 2003;12(1):42–46.

63. Franceschi S, La Vecchia C, Booth M, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. *Int J Cancer*. 1991;49(1):57–60.

64. Schildkraut JM, Cooper GS, Halabi S, et al. Age at natural menopause and the risk of epithelial ovarian cancer. *Obstet Gynecol*. 2001;98(1):85–90.

65. Polychronopoulou A, Tzonou A, Hsieh CC, et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. *Int J Cancer*. 1993;55(3):402–407.

66. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. *Am J Epidemiol*. 2002;156(4):363–373.

67. Greggi S, Parazzini F, Paratore MP, et al. Risk factors for ovarian cancer in central Italy. *Gynecol Oncol*. 2000;79(1):50–54.

68. Jordan SJ, Webb PM, Green AC. Height, age at menarche, and risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 2005;14(8):2045–2048.

69. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. *Int J Cancer*. 2001;95(6):370–374.

70. Beral V, Million Women Study Collaborators, Bull D, et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. *Lancet*. 2007;369(9574):1703–1710.

71. Garg PP, Kerlikowske K, Subak L, et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. *Obstet Gynecol*. 1998;92(3):472–479.

72. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. *Hum Reprod Update*. 2007;13(5):453–463.

73. Mills PK, Riordan DG, Cress RD, et al. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. *Cancer Detect Prev*. 2005;29(2):124–132.

74. Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. *Gynecol Oncol*. 2008;108(3):641–651.

75. Goodman LS, Gillman A. *Goodman & Gilman’s: The Pharmacological Basis of Therapeutics*. New York, NY: McGraw-Hill; 1985.